PharmaEngine
智 擎 生 技 製 藥

PharmEngine, Inc. 4162.TWO
3Q26 Investors' Conference
2026/11/05

Roger Hsieh, Associate Director of BD/Spokesperson
Jackie Chang, Senior Manager, Investor Relations

Disclaimer

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘projects,’ ‘intends,’ ‘should,’ ‘seeks,’ ‘estimates,’ ‘future,’ or similar expressions or by discussion of, among other things, strategy, goals, plans, or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. **Pricing and product initiatives of competitors**
2. **Legislative and regulatory developments and economic conditions**
3. **Delay or inability in obtaining regulatory approvals or bringing products to market**
4. **Fluctuations in currency exchange rates and general financial market conditions**
5. **Uncertainties in the discovery, development, or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products**
6. **Increased government pricing pressures**
7. **Interruptions in production**
8. **Loss of or inability to obtain adequate protection for intellectual property rights**
9. **Litigation**
10. **Loss of key executives or other employees**
11. **Adverse publicity and news coverage**

PharmaEngine cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. PharmaEngine undertakes no obligation to update publicly or revise any forward-looking statements. Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that PharmaEngine ’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of PharmaEngine, Inc.

PharmaEngine
智 擎 生 技 製 藥

AGENDA

1. 3Q 2026 Operational Highlights
2. 3Q 2026 Operational Overview
3. R&D Pipeline & Clinical Updates
4. Company Outlook
5. Q&A

3Q 2026 Operational Highlights: Sustainable Growth and Enhanced Pipeline

COMMERCIAL

ONIVYDE®
Indication expansion

1. Sales of ONIVYDE® regimen for 1L PDAC in various countries in Europe and Asia continue to boost revenue growth.
2. ONIVYDE® for 1L PDAC has been included in the Taiwan NHI reimbursement and PharmaEngine continues to expand the market

PIPELINE

New project R&D progress accelerated

1. PEP07 Phase I clinical trials for hematologic/solid tumors dose escalation safety profile analysis is completed
2. PEP08 Phase I dose escalation for solid tumors is ongoing smoothly
3. Other projects continue to move forward.

OPERATION

Operation with sustainable growth

1. 3Q26 cash and cash equivalents and current financial assets (>3 months time deposits) at amortized cost: NT$4.828bn.
2. From January to September 2026, green energy consists 30% of our energy mix.

PharmaEngine
智 擎 生 技 製 藥

3Q 2026 OPERATIONAL OVERVIEW

Sales and Royalties Drive Long-term Growth

NT$(000)

Item \ Year	2019	2020	2021	2022	2023	2024	2025	3Q 2026/3Q 2025 YOY (%)
Taiwan Sales	180,389	214,828	235,469	277,594	278,547	279,990	277,133	198,966 (+0.1%)
Royalties from Europe and Asia	133,651	271,584	419,366	376,789	426,652	543,286	627,762	512,596 (+21%)
Milestone/Sub-license Revenue	0	569,600	0	0	62,470	1,700,028	6,521	53,670 (+723%)
Total	314,040	1,056,012	654,835	654,383	767,669	2,523,304	911,416	765,232 (+22%)

3Q 2026 Financial Results

NT$(000)	1Q-3Q 2026	1Q-3Q 2025	Amount Change	% Change
Operating revenue	765,232	626,330	138,902	22%
Operating costs	51,676	35,829	15,847	44%
Gross profit	713,556	590,501	123,055	21%
Sales expenses	25,189	22,359	2,830	13%
G&A expenses	71,995	71,310	685	1%
R&D expenses	221,517	190,331	31,186	16%
Total operating expenses	318,701	284,000	34,701	12%
Operating income	394,855	306,501	88,354	29%
Total non-operating income and expenses	89,262	35,510	53,752	151%
Income before income tax	484,117	342,011	142,106	42%
Income tax expense	71,368	85,461	(14,093)	(16%)
Profit for the period	412,749	256,550	156,199	61%
EPS (NT$)	2.87	1.79	1.08	60%

PharmaEngine
智 擎 生 技 製 藥

R&D PIPELINE & CLINICAL UPDATES


Combination Therapy: A Major Trend in Modern Cancer Treatment

Combination Therapy

Combination therapy has emerged as a key approach in cancer treatment. By integrating therapies with different mechanisms of action, it can enhance treatment efficacy, extend disease control, and reduce the risk of drug resistance.

PharmaEngine Competitiveness

PharmaEngine is also exploring combination therapies with SoC, NCEs, and within our own pipeline to broaden clinical indications, enhance commercial value, and strengthen its portfolio.



Pipeline Portfolio Focuses on Precision Oncology

	Indications	Mono/Combo	Commercial Rights
ONIVYDE®	1L/2L mPDAC	Combo	Taiwan
PEP07 (CHK1i)	AML/MCL	Mono	Global
	AML	SoC	
	Solid Tumors	Mono	
	Sarcoma	+ONIVYDE®	
	Ovarian	SoC	
PEP08 (PRMT5i)	MTAP-del Tumors	Mono	Global
	PDAC, Lung	SoC	
	Glioblastoma	Mono/SoC	
PEP09	TBC	TBC	Global
PEP10	TBC	TBC	Global



PEP07 CHK1 Inhibitor: Clinical Trial Status and Plan

Target Population

Monotherapy for patients with advanced or metastatic cancers:

- Hematologic cancers
- Solid tumors

Part 1: Dose Escalation


- MTD, DLTs, safety, PK, PD, biomarker

Part 2: Dose Expansion/Combination


- AML
- Sarcoma
- Ovarian cancer

Status Update

- Operating simultaneously in Australia and Taiwan
- Monotherapy safety evaluation is completed, drug formulation conversion study is ongoing



PEP07 CHK1 Inhibitor: Combination Therapy Plan



PEP08 PRMT5 Inhibitor: Clinical Trial Status and Plan

Target Population

Patients with advanced or metastatic MTAP-deficient solid tumors

Part 1: Dose Escalation/Backfill

- MTD, DLTs, safety, PK, PD
- Preliminary ORR, DCR

Part 2: Dose Expansion


- Lung cancer, GI cancer, brain tumor, and others

Part 3: Combination

- Selected indications combo with SoCs


Status Update


- Ongoing simultaneous clinical studies in Australia, Taiwan, and South Korea
- Safety: only rare hematological and GI toxicity and management paresthesia and numbness were observed
- Preliminary efficacy showed stable disease (SD) and partial response (PR) in tumor assessment



*Backfill cohorts: Select effective dose groups for treatment (increase the number of cases).

Percentage and Number of Patients of MTAP-Del in Selected Cancers







Source: Globocan 2022

PEP08 Shows Significant Tumor Growth Inhibition in CDX Model

MIA Paca-2 CDX Model



Source: Mirati AACR 2024 poster



Source: PharmaEngine in-house data


1L and 2L Standard of Care in Metastatic PDAC

Line	Drug	Median PFS (Months)	Median OS (Months)
1L	NALIRIFOX (ONIVYDE® regimen)	7.4	11.1
1L	FOLFIRINOX	6.4	11.1
1L	Gem + nab-paclitaxel	5.6	9.2
2L	nal-IRI + 5-FU/LV (ONIVYDE® regimen)	3.1	6.1
2L	Daraxonrasib (*only approved in US*)	7.2	13.2


- **1L chemotherapy: mPFS 5.6 – 7.4 months / mOS 9.2 – 11.1 months;**
- **2L chemotherapy: mPFS 3.1 months / mOS 6.1 months;**
- **2L targeted therapy (daraxonrasib): mPFS 7.2 months / mOS 13.2 months**

Preliminary Efficacy of PEP08 in mPDAC after 12 Weeks – Case 1

65 y/o, female, MTAP-del metastatic PDAC,
received PEP08 (400mg) as 3L treatment for over 7 months



Baseline




12 weeks after PEP08 Tx,
tumor size decreased by 53%


- **ONIVYDE® regimen in 2L mPDAC treatment mPFS: 3.1 months**
- **Daraxonrasib (RASolute 302 study) 2L mPDAC treatment mPFS: 7.2 months**

Preliminary Efficacy of PEP08 in mPDAC after 12 Weeks – Case 2

71 y/o, male, MTAP-del metastatic PDAC,
received PEP08 (400mg) as 4L treatment for over 4 months



Baseline



12 weeks after PEP08 Tx,
liver lesion size decreased by 34%


- **ONIVYDE® regimen in 2L mPDAC treatment mPFS: 3.1 months**
- **Daraxonrasib (RASolute 302 study) 2L mPDAC treatment mPFS: 7.2 months**

PEP08: Potential Best in Class PRMT5 Inhibitor

	Criterion	PEP08 PharmaEngine	BMS-986504 BMS	TNG462 Tango Therapeutics	AMG-193 Amgen
General Info	Development Phase	Phase I	Phase I/II	Phase I/II	Phase I/II (Discontinued)
	Dosing	QD	QD	QD	QD
Preclinical Data	Potency	2 nM	10 nM	4 nM	16 nM
	MTAP Selectivity (Specificity)	239X	94X	45X	88X
	BBB-penetrating	YES	NO	NO	YES
Clinical Safety	Hematologic TRAEs	Anemia (preliminary)	Anemia, Neutropenia, Thrombocytopenia	Anemia Thrombocytopenia	Anemia, Neutropenia, Thrombocytopenia
	GI TRAEs	Nausea, Vomiting (preliminary)	Nausea, Diarrhea	Nausea, Diarrhea, Vomiting	Nausea, Diarrhea, Vomiting,

*Other TRAEs of PEP08 like numbness and paresthesia are manageable.

PEP08: Combination Study Plan



PharmaEngine
智 擎 生 技 製 藥

COMPANY OUTLOOK

Partnering Strategy

TARGET

1st Tier: MNC Pharma
2nd Tier: Specialty Pharma

01

PharmaEngine R&D and Value Recognition

ONIVYDE®

02

Project Awareness

- ✓ Scientific meeting: AACR, ASCO, ESMO, ASH, EHA
- ✓ Bio partnering meeting: BIO International, Bio-Europe, Bio Asia Taiwan

03

Clinical Data Reveal

- ✓ Safety and efficacy
- ✓ Enhance project value
- ✓ Establish product differentiation

Company Outlook

1. PEP07 to begin combination studies of target indications in mid-2027
2. PEP08 preliminary data read-out in 1H27
3. PEP09 and PEP10 to begin IND enabling
4. Continue communication with potential global and regional out-licensing and clinical collaboration partners
5. Collaborate with AI Drug Discovery partner to expand PEI portfolio
6. ONIVYDE® royalties will begin to expire successively

PharmaEngine
智 擎 生 技 製 藥

THANK YOU!